Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Part of paid clinical trials in Dublin, Ohio.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07091695
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab

Key Dates

Start date
May 11, 2025
Status verified
Nov 2025
Primary completion
Nov 6, 2025
Completion
Nov 6, 2025

Study Design

Enrollment
100 participants (actual)

Arms

  • Arm: Participants receiving nivolumab + relatlimab treatment
  • Arm: Participants receiving nivolumab + ipilimumab treatment

Primary Outcome Measure

Participant baseline demographics [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cardinal HealthDublinOhio43017-

Find similar trials in Dublin, OH

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Cardinal Health· Dublin, OH

Related Studies